Limba
Romanian
Romanian
English|
Ruxolitinib is the first potent, selective, JAK1/2inhibitor to enter the clinic with IC50of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagyand enhances apoptosis.
| Price | 1.064,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Ruxolitinib is the first potent, selective, JAK1/2inhibitor to enter the clinic with IC50of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagyand enhances apoptosis. |
